Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Connecticut
Clinical trial register · United States · industry-sponsored

Clinical Trials in Connecticut, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9148 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 22 Nov 2026, 03:16 UTC
9148
Studies in scope
industry-sponsored, all four open statuses
4975
Recruiting now
open to new participants
2181
Lead sponsors
across recruiting studies
Top states
California 117 Florida 107 Georgia 51 New York 51 Arizona 50

Trials with a site in Connecticut

29 of 9148 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Pfizer
Phase 3
600
Arizona, California, Connecticut, District of Columbia, Idaho, Indiana, New Jersey, Ohio
2026-09-09
Active, closed
Pfizer
Phase 3
4,701
Alabama, California, Connecticut, Florida, Georgia, Hawaii, Illinois, Iowa
2026-09-08
Not yet open
Pfizer
Phase 1
12
Connecticut
2026-07-24
Recruiting
Pfizer
Phase 1
120
Colorado, Connecticut, Florida, Georgia, Ohio, Tennessee
2026-07-01
Recruiting
Pfizer
Phase 1
133
Connecticut
2026-06-17
Recruiting
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
NCT07519655Non-Small-Cell Lung, Esophageal Cancer, Cutaneous Melanoma
Pfizer
Phase 1
250
Colorado, Connecticut, Tennessee, Virginia
2026-04-08
Active, closed
Pfizer
Phase 1
22
Connecticut
2026-03-31
Recruiting
Pfizer
Phase 1/2
132
Arkansas, California, Colorado, Connecticut, District of Columbia, Georgia, Illinois, Maryland
2026-03-11
Recruiting
Pfizer
Phase 2
770
Alabama, California, Connecticut, District of Columbia, Florida, Georgia, Hawaii, Missouri
2026-02-23
Recruiting
Pfizer
Phase 3
800
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2025-12-11
Recruiting
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
NCT07090499Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer
Pfizer
Phase 1
540
California, Connecticut, Massachusetts, Tennessee, Texas
2025-08-20
Active, closed
Pfizer
Phase 1/2
74
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Oregon
2025-06-30
Recruiting
Pfizer
Phase 3
674
Alabama, Arkansas, California, Connecticut, Florida, Illinois, Indiana, Iowa
2025-04-01
Active, closed
Pfizer
Phase 1/2
71
Arkansas, California, Colorado, Connecticut, Michigan, New Jersey, New York, Texas
2024-02-19
Active, closed
Pfizer
Phase 3
624
California, Connecticut, Florida, Illinois, Kansas, Kentucky, Louisiana, Mississippi
2023-03-03
Active, closed
Pfizer
Phase 4
319
California, Connecticut, District of Columbia, Florida, Georgia, Indiana, Louisiana, Massachusetts
2022-11-21
Recruiting
Pfizer
Observational
12,500
California, Connecticut, District of Columbia, Georgia, Kentucky, Louisiana, Maryland, Massachusetts
2022-10-27
Recruiting
Pfizer
Phase 2/3
389
Alabama, Connecticut, Florida, Georgia, Illinois, Louisiana, Michigan, Mississippi
2022-09-22
Active, closed
Pfizer
Phase 3
38,861
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho
2021-08-31
Active, closed
Pfizer
Phase 3
118
California, Connecticut, Florida, Georgia, Massachusetts, New York, Ohio, Pennsylvania
2021-08-12
Active, closed
Pfizer
Phase 3
599
Alabama, Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Illinois
2021-05-12
Recruiting
Pfizer
Phase 3
600
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2021-04-28
Recruiting
Pfizer
Phase 3
2,100
Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida
2021-01-15
Recruiting
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
NCT04606446Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer
Pfizer
Phase 2
320
Arizona, California, Connecticut, Florida, Kentucky, Tennessee, Texas, Washington
2020-11-16
Recruiting
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
NCT04557449Liposarcoma, Prostate Cancer, Advanced Breast Cancer, NSCLC (Non-small Cell Lung Cancer)
Pfizer
Phase 2
430
California, Connecticut, Massachusetts, Michigan, Tennessee, Texas
2020-09-23
Recruiting
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
NCT03460977Metastatic Castration Resistant Prostate Cancer (mCRPC), Small Cell Lung Cancer (SCLC), Follicular Lymphoma (FL)
Pfizer
Phase 1
453
Arizona, California, Connecticut, Kansas, Kentucky, Maryland, Massachusetts, Nebraska
2018-04-17
Active, closed
Pfizer
Phase 3
1,068
Alabama, Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia
2014-12-17
Rows per page Showing 1–29 of 29
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 November 2026. https://priyalifescience.com/clinical-trials-usa/state/connecticut

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,148 studies in total at the last sync on 22 Nov 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 29 of those studies with a site in Connecticut that also match the filters currently applied.

How many clinical trials are recruiting in Connecticut?

17 of the 29 studies on this page are recruiting new participants as of the 22 Nov 2026, 03:16 UTC sync. A further 1 have not yet opened recruitment, 11 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Connecticut), 29 studies
PhaseStudiesRecruitingShare
Phase 312641.4%
Phase 18527.6%
Phase 1/23110.3%
Phase 23310.3%
Observational113.4%
Phase 2/3113.4%
Phase 4103.4%

Most active sponsors

Lead sponsors with the most studies (Connecticut)
Lead sponsorStudiesRecruiting
Pfizer2917
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.